Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks’ gestation and randomized at birth to receive early high-dose recombinant human erythropoietin (rhEpo) vs placebo.

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA
Main Authors: Natalucci, Giancarlo, Latal, Bea, Koller, Brigitte, Rüegger, Christoph, Sick, Beate, Held, Leonhard, Fauchère, Jean-Claude
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Research Letter
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724553/
https://ncbi.nlm.nih.gov/pubmed/33289818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.19395
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados